BRISBANE, Calif. / Jun 07, 2024 / Business Wire / CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience.
The AviClear Investor Webinar will feature presentations by Cutera CEO Taylor Harris, EVP and CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, as well as leading dermatologists David J. Goldberg, MD, JD, and Sonia Batra, MD, MSc, MPH. The presentation will be followed by a live Q&A session for analysts and investors.
Participants can join the AviClear Investor Webinar at cutera.co/aviclearinvestor.
If participants prefer to join by telephone, they may dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. It is recommended that you call in 10 minutes prior to the scheduled start time and ask to join the Cutera webinar.
A replay will be available on Cutera’s Investor Relations website the following day.
About Cutera, Inc.
Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera strives to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.
Last Trade: | US$0.38 |
Daily Change: | 0.02 6.83 |
Daily Volume: | 41,608 |
Market Cap: | US$7.610M |
November 07, 2024 August 08, 2024 July 31, 2024 April 11, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB